Hemogenyx Advances CAR-T Therapy with Successful Second Patient Treatment

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has shared an update.

Hemogenyx Pharmaceuticals announced the successful treatment of a second patient in their Phase I clinical trial of HG-CT-1, a CAR-T therapy for relapsed/refractory acute myeloid leukemia. The treatment met initial safety criteria and showed early signs of efficacy, marking a significant step in addressing a critical unmet need in leukemia treatment. The trial aims to evaluate safety, efficacy, and overall survival, with further updates to follow as the trial progresses.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals is a publicly traded clinical-stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.

Average Trading Volume: 40,194

Technical Sentiment Signal: Sell

Current Market Cap: £7.66M

Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.